Laboratory Automation Systems Company Analysis Report 2025

(MENAFN- GlobeNewsWire - Nasdaq) Market opportunities include increased adoption of lab automation systems to address workforce shortages and improve workflow efficiency. Growth is evident in workflow automation systems, especially with cloud-based solutions from smaller vendors. Emerging sciences like CRISPR and CAR-T therapy also drive demand.

Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Laboratory Automation Systems, 2025" report has been added to ResearchAndMarkets's offering.
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources remain persistent challenges for the diagnostics sector. Automation, a broad concept encompassing processes and practices that streamline workflows, save time, and manage increasing workloads, has become a key response to these issues. By combining hardware and software systems, laboratory automation delivers multiple solutions that reduce costs, minimize human error, and enhance the reliability of clinical workflows, the development of medicines and vaccines, and the efficiency of research processes.
The market is being shaped by the growing adoption of automation systems, alongside increased demand for specialized testing and the influence of new sciences, such as CRISPR, large molecule development, and CAR-T therapy. While the automated liquid handling and sample management system markets are well-established and competitive, the workflow automation system market shows strong growth potential, driven in part by small and midsized vendors offering cloud-based orchestration for workflow management, simulation, and execution.

This Frost Radar benchmarked companies and their automated liquid handling, sample management, and workflow automation solutions. Companies were selected based on revenue share and the strength of their portfolio across at least two of these market segments. Revenue share is categorized as high (10% or more), medium (2%-9%), or low (less than 2% or absence of a strong product portfolio). The analysis highlights 13 companies that generated revenue from these solutions between 2021 and 2024.
Companies to Action

• Abbott
• Agilent Technologies
• Azenta Life Sciences
• BD
• Beckman Coulter
• Bio-Rad Laboratories
• Eppendorf
• Hamilton Company
• Revvity
• Roche Diagnostics
• Siemens Healthineers
• Tecan
• Thermo Fisher Scientific

Leveraging the Frost Radar to Empower Key Stakeholders

• Significance of Being on the Frost Radar
• CEO's Growth Team
• Investors
• Customers
• Board of Directors

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05022026004107003653ID1110701145